ASX:AC8 AusCann Group (AC8) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free AC8 Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume537,446 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.79%Price TargetN/A Stock AnalysisStock Analysis Get AusCann Group alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About AusCann GroupAusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> AC8 Stock News HeadlinesJanuary 1, 2024 | benzinga.comAusCann Group Holdings Stock (OTC:ACNNF) Dividends: History, Yield and DatesJune 2, 2023 | finance.yahoo.comAC8.AX - AusCann Group Holdings LtdApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.May 5, 2023 | fool.com.auAussie pot stock update: Here’s what you missed this monthApril 26, 2023 | fool.com.auHere are 3 recent IPOs every investor should know aboutMarch 28, 2023 | seekingalpha.comACNNF AusCann Group Holdings LtdNovember 8, 2022 | fool.com.auWhy the AusCann share price rocketed higher todayOctober 14, 2022 | fool.com.auWhy the Auscann Group Holdings Ltd share price has surged higher againApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.August 18, 2022 | fool.com.auWhy the Auscann Group Holdings Ltd share price has gone nuts todayAugust 3, 2022 | fool.com.auWhy these 4 ASX shares have started the week with HUGE declinesJuly 28, 2022 | fool.com.auWhy Auscann Group Holdings Ltd shares stormed higher todayJuly 18, 2022 | fool.com.auHere are 3 recent IPOs which SMASHED the marketJuly 18, 2022 | fool.com.auWhy the Auscann Group Holdings Ltd share price surged higher todayJuly 6, 2022 | fool.com.auPot stocks start the week strongly: Here’s what you need to knowJune 13, 2022 | fool.com.auASX pot stock update: What you need to knowJuly 29, 2021 | wsj.comAusCann Group Holdings Ltd.See More Headlines Receive AC8 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AusCann Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:AC8 CUSIPN/A CIKN/A Webwww.auscann.com.au Phone61 0 9561 8834FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.47% Return on Assets-6.70% Debt Debt-to-Equity Ratio0.10 Current Ratio49.47 Quick Ratio20.17 Sales & Book Value Annual Sales$1.55 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.05 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares440,550,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.73 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Christopher Mews A.C.I.S.B. Bus, C.P.A., Chief Financial OfficerMs. Rachel Jelleff KerrCompany SecretaryKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors AC8 Stock Analysis - Frequently Asked Questions What other stocks do shareholders of AusCann Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other AusCann Group investors own include Ardent Leisure Group Limited Stapled Securities (AAD), Cineworld Group (CINE), General Electric (GE), International Consolidated Airlines Group (IAG), Lloyds Banking Group (LLOY), Myer (MYR), Qantas Airways (QAN), Rolls-Royce Holdings plc (RR), Rackspace Technology (RXT) and Superdry (SDRY). This page (ASX:AC8) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AusCann Group Holdings Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.